https://mindmedicinelaw.com/briefing/planned-psychedelic-trial-for-meth-use-disorder-in-hiv-patients-u-s-policy-and-c-20261008-48139The Psychedelic Journalen2026-10-08T22:04:26.507266+00:00Planned Psychedelic Trial for Meth Use Disorder in HIV+ Patients: U.S. Policy and Clinical Implicationsmethamphetamine use disorder, psychedelic clinical trial, hiv and addiction, fda policy, psychedelic-assisted therapy, public health, neuroplasticity, risk and ethics, addiction medicine, clinical researchhttps://mindmedicinelaw.com/briefing/filament-s-psilocybin-pex010-supply-deal-us-clinical-trial-implications-20261008-47964The Psychedelic Journalen2026-10-08T15:08:59.772047+00:00Filament's Psilocybin PEX010 Supply Deal: US Clinical Trial Implicationsfilament health, pex010, psilocybin supply, us clinical trials, fda compliance, gmp manufacturing, dea regulation, psychedelic research infrastructurehttps://mindmedicinelaw.com/briefing/fda-considers-ibogaine-trial-design-as-psychedelic-industry-eyes-commercializati-20261008-47961The Psychedelic Journalen2026-10-08T15:07:50.342274+00:00FDA Considers Ibogaine Trial Design as Psychedelic Industry Eyes Commercializationfda ibogaine trial design, psychedelic commercialization, compass pathways pricing, lsd brand names, psilocybin trademarks, psychedelic policy us, clinical trial safety, market access psychedelics, regulatory precedent, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/expanding-u-s-psychedelic-policy-public-health-and-non-clinical-use-20261007-47839The Psychedelic Journalen2026-10-08T15:09:32.478134+00:00Expanding U.S. Psychedelic Policy: Public Health and Non-Clinical Usepsychedelic policy, public health, non-clinical use, us drug law, harm reduction, indigenous practices, mental health, historical context, regulatory frameworks, community accesshttps://mindmedicinelaw.com/briefing/clearmind-engages-fda-psychedelic-therapy-policy-in-focus-20261007-47962The Psychedelic Journalen2026-10-08T15:09:14.073531+00:00Clearmind Engages FDA: Psychedelic Therapy Policy in Focusclearmind, fda, psychedelic therapy, regulatory policy, industry submissions, clinical trials, us drug regulation, stakeholder engagement, drug development, public healthhttps://mindmedicinelaw.com/briefing/2r-6r-hnk-reverses-ptsd-like-behaviors-in-female-rats-20261007-47881The Psychedelic Journalen2026-10-08T15:08:24.229961+00:00(2R,6R)-HNK Reverses PTSD-like Behaviors in Female Rats2r6r-hydroxynorketamine, ptsd, blast injury, female veterans, preclinical research, glutamate signaling, animal models, neurobehavioral disorders, clinical translationhttps://mindmedicinelaw.com/briefing/systematic-review-ketamine-for-bpd-depression-and-suicidality-20261007-47880The Psychedelic Journalen2026-10-08T15:08:07.351964+00:00Systematic Review: Ketamine for BPD, Depression, and Suicidalityketamine, borderline personality disorder, bpd, systematic review, depression, suicidality, clinical trials, psychedelic research, safety, evidence gapshttps://mindmedicinelaw.com/briefing/usc-clinical-trial-explores-psilocybin-and-mindfulness-for-depression-20261007-47963The Psychedelic Journalen2026-10-08T15:06:47.238212+00:00USC Clinical Trial Explores Psilocybin and Mindfulness for Depressionpsilocybin, mindfulness meditation, depression, clinical trial, usc, keck school of medicine, psychedelic-assisted therapy, fda, mental health, combination therapyhttps://mindmedicinelaw.com/briefing/clearmind-s-fda-submission-psychedelic-policy-dialogue-in-the-u-s-20261007-47786The Psychedelic Journalen2026-10-07T22:04:45.003925+00:00Clearmind’s FDA Submission: Psychedelic Policy Dialogue in the U.S.clearmind, fda, psychedelic policy, industry engagement, psychedelic regulation, clinical trials, u.s. federal law, drug development, public health, private sectorhttps://mindmedicinelaw.com/briefing/clearmind-s-psychedelic-therapy-recommendations-fda-policy-engagement-in-the-us-20261007-47626The Psychedelic Journalen2026-10-07T15:06:47.670175+00:00Clearmind’s Psychedelic Therapy Recommendations: FDA Policy Engagement in the USclearmind, fda policy, psychedelic therapy, industry submissions, us regulatory framework, drug development guidance, clinical trials, stakeholder engagementhttps://mindmedicinelaw.com/briefing/usc-launches-psilocybin-mindfulness-trial-for-depression-20261007-47628The Psychedelic Journalen2026-10-07T15:06:00.251441+00:00USC Launches Psilocybin-Mindfulness Trial for Depressionusc psilocybin trial, mindfulness and psychedelics, depression clinical research, psychedelic-assisted therapy, fda breakthrough therapy, academic psychedelic research, mental health policy, clinical trial protocolshttps://mindmedicinelaw.com/briefing/modern-antidepressants-and-psychedelic-mechanisms-clinical-and-policy-implicatio-20261006-47882The Psychedelic Journalen2026-10-08T22:05:03.678976+00:00Modern Antidepressants and Psychedelic Mechanisms: Clinical and Policy Implicationsmodern antidepressants, esketamine, glutamatergic mechanisms, neuroplasticity, psychedelic science, personalized psychiatry, clinical trial design, safety benchmarks, treatment-resistant depression, bdnfhttps://mindmedicinelaw.com/briefing/ego-dissolution-integration-framework-new-guidance-for-psychedelic-therapy-20261006-47841The Psychedelic Journalen2026-10-08T22:04:41.133338+00:00Ego Dissolution Integration Framework: New Guidance for Psychedelic Therapyego dissolution, psychedelic therapy, integration framework, clinical guidelines, predictive coding theory, acceptance and commitment therapy, internal family systems, interpersonal neurobiology, risk mitigation, therapist traininghttps://mindmedicinelaw.com/briefing/counselor-training-gaps-in-psychedelic-assisted-therapy-us-policy-and-practice-i-20261006-47840The Psychedelic Journalen2026-10-08T15:08:40.063527+00:00Counselor Training Gaps in Psychedelic-Assisted Therapy: US Policy and Practice Implicationspsychedelic-assisted therapy, counselor training, professional competencies, mental health policy, regulatory standards, public health risk, interdisciplinary collaboration, education gaps, clinical supervisionhttps://mindmedicinelaw.com/briefing/intranasal-penk-mscs-show-promise-for-opioid-dependence-in-rats-20261006-47563The Psychedelic Journalen2026-10-07T15:07:05.441283+00:00Intranasal PENK-MSCs Show Promise for Opioid Dependence in Ratsproenkephalin, mesenchymal stem cells, intranasal delivery, morphine dependence, neurotrophic factors, addiction treatment, preclinical research, substance use disorder, cell-based therapyhttps://mindmedicinelaw.com/briefing/ketamine-s-distinct-short-term-effects-on-insomnia-and-anxiety-in-trd-20261006-47561The Psychedelic Journalen2026-10-07T15:06:14.654925+00:00Ketamine’s Distinct Short-Term Effects on Insomnia and Anxiety in TRDketamine, treatment-resistant depression, insomnia, anxiety, clinical trial, psychiatric protocols, sleep mechanisms, FDA regulation, symptom-specific effectshttps://mindmedicinelaw.com/briefing/group-psychedelic-assisted-therapy-evidence-gaps-and-policy-implications-20261006-47516The Psychedelic Journalen2026-10-07T15:05:23.865407+00:00Group Psychedelic-Assisted Therapy: Evidence, Gaps, and Policy Implicationsgroup psychedelic therapy, systematic review, mental health, cost-effectiveness, peer support, randomized controlled trials, policy implications, clinical protocols, equity in therapy, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-for-cancer-related-anxiety-evidence-and-policy-outl-20261005-47520The Psychedelic Journalen2026-10-07T15:07:22.155343+00:00Psychedelic-Assisted Therapy for Cancer-Related Anxiety: Evidence and Policy Outlookpsychedelic-assisted therapy, cancer-related anxiety, integrative oncology, clinical trials, mental health guidelines, psilocybin, emerging therapies, regulatory policy, methodological challengeshttps://mindmedicinelaw.com/briefing/amygdala-and-anxiety-threat-probability-not-uncertainty-drives-neural-response-20261005-47564The Psychedelic Journalen2026-10-07T15:06:31.170553+00:00Amygdala and Anxiety: Threat Probability, Not Uncertainty, Drives Neural Responseamygdala function, threat probability, anxiety neurobiology, clinical trial design, biomarker development, psychedelic research, extended amygdala, BST, Ce, translational neurosciencehttps://mindmedicinelaw.com/briefing/multidose-psilocybin-for-ocd-johns-hopkins-open-label-trial-insights-20261005-47518The Psychedelic Journalen2026-10-07T15:05:43.882804+00:00Multidose Psilocybin for OCD: Johns Hopkins Open-Label Trial Insightspsilocybin, obsessive-compulsive disorder, johns hopkins, clinical trial, multidose protocol, psychedelic therapy, y-bocs, regulatory pathways, safety and efficacy, treatment-resistant ocdhttps://mindmedicinelaw.com/briefing/psychedelics-for-disorders-of-consciousness-u-s-neurotherapeutics-outlook-20261003-47903The Psychedelic Journalen2026-10-08T22:05:25.562088+00:00Psychedelics for Disorders of Consciousness: U.S. Neurotherapeutics Outlookpsychedelics, disorders of consciousness, neurotherapeutics, clinical trials, brain connectivity, FDA regulation, research ethics, serotonin 2A receptor, EEG complexity, NIH fundinghttps://mindmedicinelaw.com/briefing/novel-5-ht2a-agonists-patent-disclosure-signals-next-gen-psychedelic-therapeutic-20261002-47905The Psychedelic Journalen2026-10-08T22:05:42.689735+00:00Novel 5-HT2A Agonists: Patent Disclosure Signals Next-Gen Psychedelic Therapeutics5-ht2a agonists, psychedelic drug development, aminocyclohexenyl-6,6-bicyclic compounds, depression treatment research, anxiety therapeutics, substance use disorder, patent disclosure, clinical translation, regulatory pathways, novel psychoactive compoundshttps://mindmedicinelaw.com/briefing/ibogaine-induces-neural-repair-via-metabolic-preconditioning-in-mice-20261002-47907The Psychedelic Journalen2026-10-08T15:07:12.500550+00:00Ibogaine Induces Neural Repair via Metabolic Preconditioning in Miceibogaine, metabolic preconditioning, synaptic plasticity, neural repair, mitoKv1.3, sigma-2 receptor, preclinical study, psychedelic research, neuropsychiatric disorders, clinical trial designhttps://mindmedicinelaw.com/briefing/astrocytic-connexin-43-a-novel-target-in-parkinson-s-disease-pathology-20261001-47910The Psychedelic Journalen2026-10-08T22:05:59.837480+00:00Astrocytic Connexin 43: A Novel Target in Parkinson’s Disease Pathologyconnexin 43, astrocytes, parkinson's disease, neuroinflammation, glial targets, danegaptide, neuroplasticity, psychedelic therapeutics, clinical translation, gap junctionshttps://mindmedicinelaw.com/briefing/short-acting-tryptamines-clinical-evidence-and-regulatory-outlook-20261001-47857The Psychedelic Journalen2026-10-08T15:07:32.968046+00:00Short-Acting Tryptamines: Clinical Evidence and Regulatory Outlookshort-acting tryptamines, n,n-dmt, 5-meo-dmt, zalsupindole, treatment-resistant depression, phase 2b trial, neuroplasticity, hallucinogenic experience, regulatory strategy, adverse events